OncoZenge Feed

2026-07-24 16:15:00 OncoZenge Extends the Payment Deadline for Remaining Subscription Proceeds 6,86 SEK | -4,06% | 0,06 MSEK

2026-07-17 16:45:00 OncoZenge Extends the Payment Deadline for Remaining Subscription Proceeds 6,10 SEK | -5,28% | 0,12 MSEK

2026-07-10 17:15:00 OncoZenge has received partial payment of SEK 5.0 million for subscription proceeds in directed share issue and extends payment deadline 6,59 SEK | -4,49% | 0,14 MSEK

2026-07-07 15:25:00 OncoZenge AB Announces Enrollment of First Patient in Pivotal Phase III BEAM-Pain Trial of BupiZenge™ 6,85 SEK | -2,97% | 0,37 MSEK

2026-07-03 17:10:00 OncoZenge Extends the Payment Deadline for Subscription Proceeds 7,22 SEK | -0,96% | 0,33 MSEK

2026-06-26 14:15:00 OncoZenge Extends the Payment Deadline for Subscription Proceeds 7,47 SEK | +0,95% | 0,23 MSEK

2026-06-05 15:10:00 OncoZenge resolves on a directed share issue to Sichuan Yangtian Bio-Pharmaceutical pursuant to existing investment agreement 6,32 SEK | -0,32% | 0,28 MSEK

2026-06-03 09:30:00 OncoZenge AB Appoints Linda Nord as Head of Regulatory Affairs 6,49 SEK | -3,42% | 0,21 MSEK

2026-06-02 09:50:00 OncoZenge Receives CTA Approval Milestone Payment From Molteni Farmaceutici 6,72 SEK | +6,67% | 0,59 MSEK

2026-05-27 15:15:00 KOMMUNIKÉ FRÅN ÅRSSTÄMMA I ONCOZENGE 6,73 SEK | -10,27% | 0,70 MSEK

2026-05-27 15:15:00 BULLETIN FROM THE ANNUAL GENERAL MEETING OF ONCOZENGE 6,73 SEK | -10,27% | 0,70 MSEK

2026-05-26 11:20:00 OncoZenge Receives European Regulatory Approval to Start Pivotal Phase III Trial of BupiZenge™ 7,50 SEK | -0,92% | 2,13 MSEK

2026-05-26 08:00:00 OncoZenge AB Interim Report January 1 - March 31, 2026 7,50 SEK | -0,92% | 2,13 MSEK

2026-05-22 07:00:00 OncoZenge enters into a loan agreement of SEK 2 million with Linc AB 7,28 SEK | +2,82% | 0,42 MSEK

2026-05-19 13:40:00 OncoZenge Provides Regulatory Update on BupiZenge™ Phase III Trial 6,80 SEK | +3,03% | 0,39 MSEK

2026-04-30 08:00:00 OncoZenge AB publicerar årsredovisning för 2025 6,00 SEK | -5,96% | 0,09 MSEK

2026-04-30 08:00:00 OncoZenge AB Publishes Annual Report for 2025 6,00 SEK | -5,96% | 0,09 MSEK

2026-04-28 14:50:00 OncoZenge Receives Conditional Acceptance for the Clinical Phase III Trial (‘BEAM-Pain’) of BupiZenge™ from European Authorities 6,17 SEK | +3,70% | 0,35 MSEK

2026-04-24 08:00:00 Notice of the Annual General Meeting of OncoZenge AB (publ) 5,81 SEK | +1,75% | 0,20 MSEK

2026-04-24 08:00:00 Kallelse till årsstämma i OncoZenge AB (publ) 5,81 SEK | +1,75% | 0,20 MSEK

2026-04-02 12:55:00 OncoZenge Confirms Submission of Responses to EMA on the BupiZenge™ Phase III Trial (BZ003) 5,70 SEK | -0,35% | 0,02 MSEK

2026-04-01 09:15:00 OncoZenge Reports Positive Stability Results for BupiZenge™ as Key Enabler for the Upcoming Phase III Trial 5,72 SEK | +3,81% | 0,22 MSEK

2026-02-26 08:00:00 OncoZenge AB Year-end Report January 1 – December 31, 2025 5,99 SEK | +3,81% | 0,07 MSEK

2026-02-12 10:22:00 OncoZenge Receives Investment Capital From Yangtian Bio-Pharmaceutical 5,81 SEK | +2,83% | 0,19 MSEK

2026-02-04 09:40:00 OncoZenge AB Unveils Key Insights from UCLA Patient Engagement Study on Oral Mucositis Pain Management 5,64 SEK | +10,16% | 0,19 MSEK

2026-02-02 09:30:00 OncoZenge AB Appoints Dr. Marie-Louise Fjällskog as Chief Medical Officer 5,16 SEK | -0,58% | 0,07 MSEK

2026-01-30 15:40:00 OncoZenge AB Reports Positive Initial Stability Results for the BupiZenge™ Technology Batch, Advancing Toward Clinical Trials 5,19 SEK | -4,07% | 0,23 MSEK

2026-01-22 19:19:00 OncoZenge enters into convertible loan agreement with Linc AB and gives an update on the payment of subscription proceeds 5,64 SEK | +8,67% | 0,22 MSEK

2026-01-21 17:32:00 OncoZenge announces uncertainty regarding payment of subscription proceeds and liquidity impact 5,19 SEK | -11,13% | 0,76 MSEK

2025-12-19 08:50:00 OncoZenge resolves on a directed share issue to Sichuan Yangtian Bio-Pharmaceutical pursuant to existing investment agreement 6,17 SEK | +0,98% | 0,10 MSEK

2025-12-18 17:23:00 OncoZenge Submits Clinical Trial Application for Pivotal Phase III Trial (BZ003) of BupiZenge™ 6,11 SEK | -4,08% | 0,15 MSEK

2025-12-03 08:45:00 OncoZenge and Molteni expand partnership: Molteni to assume commercial manufacturing of BupiZenge™ for Europe 6,71 SEK | +10,18% | 0,67 MSEK

2025-11-17 10:00:00 OncoZenge Strengthens Advisory Board with Co-Inventor Dr. Torben Mogensen Ahead of Phase III Trial for BupiZenge™ 5,90 SEK | -7,38% | 0,04 MSEK

2025-10-30 08:00:00 OncoZenge AB Interim Report January 1 – September 30, 2025 5,59 SEK | +0,54% | 0,12 MSEK

2025-10-09 08:45:00 OncoZenge AB: First Patient Enrolled in UCLA Patient Engagement Study 5,99 SEK | +6,77% | 0,51 MSEK

2025-10-08 19:50:00 OncoZenge AB Nomination Committee Appointed 5,99 SEK | +6,77% | 0,51 MSEK

2025-09-22 15:20:00 OncoZenge AB - Capital Markets Day 2025 On-Demand Video Now Available 6,11 SEK | -3,02% | 0,39 MSEK

2025-09-17 08:50:00 OncoZenge AB Enters into Collaboration with UCLA for Patient Engagement Study on BupiZenge™ 6,30 SEK | +1,78% | 0,33 MSEK

2025-09-10 17:10:00 OncoZenge AB appoints LINK Medical as CRO for BupiZenge™ Phase III execution 6,85 SEK | +5,71% | 1,38 MSEK

2025-08-27 16:00:00 Invitation to OncoZenge's Capital Markets Day on 18 September 2025 6,59 SEK | +1,07% | 0,60 MSEK

2025-08-21 08:00:00 OncoZenge AB Interim Report January 1 – June 30, 2025 7,62 SEK | +3,11% | 0,55 MSEK

2025-08-13 11:35:00 OncoZenge Event Calendar September – December 2025 6,20 SEK | -3,58% | 0,24 MSEK

2025-08-13 10:55:52 OncoZenge ändrar bolagets rapportering till engelska 6,20 SEK | -3,58% | 0,24 MSEK

2025-08-13 10:55:52 OncoZenge Changes Reporting Language to English 6,20 SEK | -3,58% | 0,24 MSEK

2025-07-30 08:50:00 OncoZenge Provides Market and Strategy Update 6,68 SEK | +1,37% | 0,34 MSEK

2025-07-21 09:50:00 OncoZenge Appoints Meribel Pharma as CDMO for BupiZenge™ Phase 3 Project 6,95 SEK | +2,06% | 0,23 MSEK

2025-07-21 09:50:00 OncoZenge utser Meribel Pharma som CDMO för BupiZenge™ Fas 3-projektet 6,95 SEK | +2,06% | 0,23 MSEK

2025-07-17 08:45:00 OncoZenge och Molteni Farmaceutici undertecknar tilläggsavtal för att fokusera BupiZenge™ fas 3-projekt i Europa 6,52 SEK | -3,26% | 0,59 MSEK

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode